Key result
Large real-world cohort assesses ventricular arrhythmia incidence linked to intracoronary papaverine administration.
Why the study?
The precise incidence of intracoronary papaverine-induced ventricular arrhythmias and their precipitating factors had not been firmly established.
What is the incidence of ventricular arrhythmias related to intracoronary papaverine administration in a large real-world cohort?
Cohort
What is the incidence of ventricular arrhythmias related to intracoronary papaverine administration in a large real-world cohort?
Large real-world cohort yields incidence estimates for papaverine-related arrhythmias; leaves open optimal safety protocols in coronary testing.
Papaverine has been proposed as the ideal coronary vasodilator due to its ease of use, low cost, and capacity to induce steady‐state maximal hyperemia. However, in a small proportion of patients, ventricular arrhythmias may occur, possibly related to the interaction of papaverine with contrast agents or heparin. The precise incidence of these arrhythmias and their precipitating factors have not been firmly established. Accordingly, we aimed to assess the incidence of ventricular arrhythmias related to intracoronary papaverine administration and to identify any clinical or procedural risk factors in a large real‐world cohort.
No takes yet. Share an insight, caveat, or question.
Corradetti et al. (2026) conducted a cohort in Coronary vasodilation. Intracoronary papaverine was evaluated on Incidence of ventricular arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: